Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac)

Xue Li; Kuan Peng; Franco W T Cheng; David C L Lam; Ching Lung Cheung; Celine S L Chui; Francisco T T Lai; Eric Y F Wan; Carlos K H Wong; Tiantian Ma; Samson H H Yum; Esther W Y Chan; Jian Dong Huang; Chak Sing Lau; Mary S M Ip; Ian C K Wong

doi:10.1016/j.jinf.2022.12.016

Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac)

J Infect. 2023 Mar;86(3):256-308. doi: 10.1016/j.jinf.2022.12.016. Epub 2022 Dec 17.

Authors

Affiliations

¹ Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong; Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong; Laboratory of Data Discovery for Health (D(2)4H), Hong Kong Science Park, Hong Kong.
² Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong.
³ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong.
⁴ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong; Laboratory of Data Discovery for Health (D(2)4H), Hong Kong Science Park, Hong Kong.
⁵ Laboratory of Data Discovery for Health (D(2)4H), Hong Kong Science Park, Hong Kong; School of Nursing, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong; School of Public Health, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong.
⁶ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong; Laboratory of Data Discovery for Health (D(2)4H), Hong Kong Science Park, Hong Kong; Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong.
⁷ Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong.
⁸ School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong.
⁹ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong; Laboratory of Data Discovery for Health (D(2)4H), Hong Kong Science Park, Hong Kong; Research Department of Practice and Policy, UCL School of Pharmacy, Hong Kong. Electronic address: wongick@hku.hk.

No abstract available

Keywords: COVID-19 vaccines; Innate immunity; Tuberculosis.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Viral
BNT162 Vaccine
COVID-19 Vaccines / adverse effects
COVID-19* / prevention & control
Humans
SARS-CoV-2 / genetics
Tuberculosis*
Vaccination

Substances

sinovac COVID-19 vaccine
COVID-19 Vaccines
BNT162 Vaccine
Antibodies, Viral